| Literature DB >> 35956092 |
Shu-Han Tsao1, Chien-Ho Wang2, Horng-Heng Juang1,3,4, Yu-Hsiang Lin1, Pei-Shan Yang1, Phei-Lang Chang1, Chien-Lun Chen1, Chen-Pang Hou1,3,5,6.
Abstract
Xanthogranulomatous pyelonephritis (XGP) is a rare inflammatory disease often associated with high morbidity and mortality. Whether the midline transperitoneal or the flank retroperitoneal approach is superior remains unknown. We searched through pathology databases and reviewed 86 patients with an XGP diagnosis from 2000 to 2021 at our institution. After the patients who did not meet the inclusion criteria were excluded, 35 patients who had undergone nephrectomy through the midline transperitoneal or the flank retroperitoneal laparotomy approach were recruited. Nine (25.71%) of the thirty-five patients underwent nephrectomy through a midline approach, whereas twenty-six (74.29%) received a flank approach. Patients in the midline approach group had a longer surgical time (p = 0.03) than those in the flank approach group. In addition, patients in the flank approach group took less time after surgery to resume oral intake than those in the midline approach group (p = 0.01). No significant differences in the rates of intraoperative and postoperative complications such as peritonitis or intraabdominal infection were observed between the groups. For the patients with XGP who are good candidates for surgery, nephrectomy is a relatively safe surgical treatment method. Both surgical methods produced favorable surgical outcomes, and the patients who received these methods had similar complication rates.Entities:
Keywords: XGP; nephrectomy; retroperitoneal; transperitoneal; xanthogranulomatous pyelonephritis
Year: 2022 PMID: 35956092 PMCID: PMC9369389 DOI: 10.3390/jcm11154476
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Flowchart of patient enrollment.
Demographic and clinical characteristics of patients.
| Variable | All | Group I | Group II | |
|---|---|---|---|---|
| Female, N (%) | 31/35 (88.5%) | 8/9 (88.9%) | 23/26 (88.4%) | 0.73 |
| Age, years old (mean ± SD) | 62.0 ± 9.8 | 61.3 ± 10.6 | 62.2 ± 9.5 | 0.43 |
| BMI, kg/m2 (mean ± SD) | 26.0 ± 4.3 | 28.3 ± 3.2 | 25.7 ± 4.5 | 0.05 |
| Comorbidity | ||||
| Hypertension, n (%) | 17/35 (48.6%) | 6/9 (66.7%) | 9/26 (34.6%) | 0.19 |
| Diabetes mellitus, n (%) | 15/35 (42.8%) | 5/9 (55.6%) | 10/26 (38.4%) | 0.31 |
| Hemodialysis, n (%) | 2/35 (5.7%) | 1/9 (11.1%) | 1/26 (3.8%) | 0.45 |
| ASA Classification (mean ± SD) | 2.6 ± 0.5 | 2.89 ± 0.3 | 2.54 ± 0.6 | 0.02 |
| Preoperative laboratory data | ||||
| White blood cell, /mm3 (mean ± SD) | 9757 ± 3510 | 9525 ± 944 | 9850 ± 4106 | 0.41 |
| Hemoglobin, g/dL (mean ± SD) | 9.3 ± 1.4 | 9.5 ± 1.3 | 9.2 ± 1.5 | 0.36 |
| Creatinine clearance, ml/min (mean ± SD) | 62.1 ± 35.2 | 62.8 ± 47.6 | 61.8 ± 28.0 | 0.49 |
| Initial presentations | ||||
| Urinary tract infection, n (%) | 23/35 (65.7%) | 6/9 (66.7%) | 17/26 (65.3%) | 0.64 |
| Abdominal pain, n (%) | 27/35 (77.1%) | 7/9 (77.8%) | 20/26 (76.9%) | 0.67 |
| Hematuria, n (%) | 15/35 (42.9%) | 2/9 (22.2%) | 13/26 (50.0%) | 0.14 |
| Fever, n (%) | 12/35 (34.3%) | 3/9 (33.3%) | 9/26 (34.6%) | 0.64 |
| Preoperative diagnosis | ||||
| Radiographic XGP, n (%) | 4/35 (11.4%) | 0/9 (0.0%) | 4/26 (15.4%) | 0.29 |
| Renal calculus, n (%) | 24/35 (68.6%) | 3/9 (33.3%) | 21/26 (80.8%) | 0.02 |
| Hydronephrosis, n (%) | 23/35 (65.7%) | 5/9 (55.6%) | 18/26 (69.2%) | 0.36 |
| Renal mass, n (%) | 8/35 (22.9%) | 5/9 (55.6%) | 3/26 (11.5%) | 0.02 |
| Malek and Elder classification (mean ± SD) | 2.63 (0.54) | 3.0 (0) | 2.5 (0.57) | <0.05 |
| Preoperative drainage placement, n (%) | 14/35 (40.0%) | 3/9 (33.3%) | 11/26 (42.3%) | 0.47 |
BMI, body mass index. ASA, American Society of Anesthesiologists. XGP, xanthogranulomatous pyelonephritis.
Perioperative and postoperative results.
| Variable | All | Group I | Group II | |
|---|---|---|---|---|
| All cause of 30-day mortality, n (%) | 0/35 (0.0%) | 0/9 (0.0%) | 0/26 (0.0%) | N/A |
| Estimated blood loss (EBL), ml (mean ± SD) | 737.1 ± 606.8 | 950.0 ± 679.9 | 663.5 ± 560.8 | 0.13 |
| Blood transfusion during surgery, n (%) | 19/33 (57.6%) | 8/9 (88.9%) | 11/24 (45.8%) | 0.28 |
| PRBC, U (mean ± SD) | 3.2 ± 2.7 | 4.4 ± 3.2 | 2.7 ± 2.3 | 0.09 |
| FFP, U (mean ± SD) | 1.8 ± 2.2 | 2.2 ± 2.7 | 1.6 ± 2.0 | 0.28 |
| Operative duration, minutes (mean ± SD) | 250.9 ± 96.6 | 322.3 ± 114.3 | 226.2 ± 75.3 | 0.03 |
| Kidney specimen volumn, grams (mean ± SD) | 388.4 ± 237.7 | 531.9 ± 292.7 | 338.7 ± 191.9 | 0.39 |
| Intraoperative complications, n (%) | 2/35 (5.7%) | 1/9 (11.1%) | 1/26 (3.8%) | 0.45 |
| Postoperative complications, n (%) | 5/35 (14.3%) | 2/9 (22.2%) | 3/26 (11.5%) | 0.38 |
| Clavien–Dindo classification greater than three, n (%) | 4/35 (11.4%) | 1/9 (11.1%) | 3/26 (11.5%) | 0.73 |
| Duration of postoperative drainage placement time, day (mean ± SD) | 10 ± 7.3 | 11.6 ± 9.4 | 9.4 ± 6.2 | 0.28 |
| Duration of postoperative analgesic use, day (mean ± SD) | 16.9 ± 6.6 | 17.9 ± 7.3 | 16.6 ± 6.4 | 0.33 |
| Duration of postoperative antibiotics, day (mean ± SD) | 16.1 ± 7.6 | 16.3 ± 8.4 | 16.0 ± 7.3 | 0.47 |
| Time to first oral diet, day (mean ± SD) | 3.3 ± 1.5 | 4.6 ± 1.6 | 2.8 ± 1.3 | 0.01 |
| ICU admission, n (%) | 4/35 (11.4%) | 1/9 (11.1%) | 3/26 (11.5%) | 0.73 |
| Length of hospitalization after surgery, day (mean ± SD) | 11.3 ± 7.2 | 12.9 ± 8.9 | 10.7 ± 6.3 | 0.41 |
| Return to ER in 3 months, n (%) | 1/35 (2.9%) | 0/9 (0.0%) | 1/26 (3.8%) | 0.74 |
N/A, Not Applicable. PRBC, packed red blood cells. FFP, fresh frozen plasma. SD, standard deviation. ICU, intensive care unit. ER, emergency room.
Pathogens detected in preoperative urine and perinephric abscess cultures.
| Pathogen | All | Group I | Group II |
|---|---|---|---|
| Negative culture results, n (%) | 4 (11.4%) | 1 (11.1%) | 3 (11.5%) |
| Bacteroides fragilis, n (%) | 3 (8.6%) | 1 (11.1%) | 2 (7.7%) |
| Citrobacter amalonaticus, n (%) | 1 (2.9%) | 0 (0.0%) | 1 (3.8%) |
| Enterobacter aerogenes, n (%) | 2 (5.7%) | 1 (11.1%) | 1 (3.8%) |
| Escherichia coli, n (%) | 18 (51.4%) | 7 (77.8%) | 11 (42.3%) |
| Klebsiella pneumoniae, n (%) | 2 (5.7%) | 1 (11.1%) | 1 (3.8%) |
| Proteus mirabilis, n (%) | 11 (31.4%) | 2 (22.2%) | 9 (34.6%) |
| Pseudomonas aeruginosa, n (%) | 2 (5.7%) | 2 (22.2%) | 0 (0.0%) |
| Streptococcus agalactiae, n (%) | 6 (17.1%) | 0 (0.0%) | 6 (23.0%) |
| Staphylococcus aureus, n (%) | 1 (2.9%) | 0 (0.0%) | 1 (3.8%) |
| Viridans streptococcus | 2 (5.7%) | 0 (0.0%) | 2 (7.7%) |
| Candida albicans, n (%) | 1 (2.9%) | 0 (0.0%) | 1 (3.8%) |
| Multiple organisms, n (%) | 14 (40.0%) | 3 (33.3%) | 11 (42.3%) |